Savara (SVRA) EBITDA Margin (2009 - 2026)
Savara's EBITDA Margin came in at -4932.93% for Q2 2026, down 1536.95 percentage points from -3395.98% a year earlier and down 1261.60 percentage points from the prior quarter.
Powered by 
Analysis
Savara (SVRA) EBITDA Margin (2009 - 2026) Analysis & Trends
Over the trailing twelve months to Jun 30, 2026, Savara reported EBITDA Margin of -3943.12%, down 2133.16 percentage points year-over-year; for FY2025, it came in at -2955.48%, down 1365.95 percentage points from FY2024.
- EBITDA Margin carries a five-year change of +15930.90 percentage points (FY2020 to FY2025).
- Going back by year, EBITDA Margin was -1589.53% in FY2024 (-244.65 pp) and -1344.88% in FY2023.
- The five-year range for quarterly EBITDA Margin is -5491.24% (Q3 2025) to -1154.05% (Q4 2023).
- Year-over-year, EBITDA Margin has declined for four consecutive quarters, with an average year-over-year change of -1841.53 percentage points over the last five quarters.
- Business Quant data shows SVRA's EBITDA Margin at -3671.33% (Q1 2026), -2786.95% (Q4 2025) and -5491.24% (Q3 2025) in the three quarters before Q2 2026.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,348.13 Bn | 1,321.74 Bn | 20.46 Bn | 36.69% |
| 2 | Johnson & Johnson | 675.90 Bn | 595.76 Bn | 17.30 Bn | 32.68% |
| 3 | AbbVie | 519.45 Bn | 487.50 Bn | 13.12 Bn | 46.88% |
| 4 | Merck | 364.95 Bn | 327.95 Bn | 13.19 Bn | 40.60% |
| 5 | Novartis Ag | 311.58 Bn | 285.16 Bn | - | - |
| 6 | Astrazeneca | 289.34 Bn | 262.94 Bn | 13.26 Bn | 39.77% |
| 7 | Amgen | 251.64 Bn | 203.30 Bn | 7.58 Bn | 46.62% |
| 8 | Gilead Sciences | 212.05 Bn | 187.07 Bn | 6.73 Bn | 50.63% |
| 9 | Pfizer | 167.35 Bn | 115.00 Bn | 12.56 Bn | 42.49% |
| 10 | Savara | 1.09 Bn | 407.27 Mn | - | -8,584.95% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2026 | -8,584.95% |
| Jun 30, 2026 | -4,932.93% |
| Mar 31, 2026 | -3,671.33% |
| Dec 31, 2025 | -2,786.95% |
| Sep 30, 2025 | -5,491.06% |
| Jun 30, 2025 | -3,395.98% |
| Mar 31, 2025 | -1,891.52% |
| Dec 31, 2024 | -1,624.36% |
| Sep 30, 2024 | -1,233.26% |
| Dec 31, 2023 | -1,154.05% |
| Dec 31, 2022 | -1,758.96% |
| Dec 31, 2020 | -1,282,000.00% |
| Sep 30, 2020 | -4,140.63% |
| Sep 30, 2019 | -244,920.00% |
| Jun 30, 2019 | -70,248.39% |
| Dec 31, 2018 | -11,088.03% |
| Sep 30, 2018 | -11,304.50% |
| Mar 31, 2017 | -4,956.38% |
| Dec 31, 2016 | -992.25% |
| Sep 30, 2016 | -5,757.78% |
API Access
Savara EBITDA Margin API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=ebitda-margin&ticker=SVRA&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "ebitda-margin", "ticker": "SVRA", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=ebitda-margin&ticker=SVRA&period=max&api_key=YOUR_API_KEY");
const data = await res.json();